SAHPRA’s Friday deadline: why companies should, and should not, join the device-registration test

The European Commission’s EU Public Procurement Act would make quality, not price, the default for public tenders. EFPIA supports the shift, with one warning: resilience should not become local-content rules. #SyenzaNews #EUProcurement #Medicines #MarketAccess #HealthPolicy

An independent UK commission has published its recommendations for regulating AI in healthcare. The report calls for staged approvals and continuous real-world monitoring, alongside stronger enforcement powers for the MHRA. #SyenzaNews #AI #Healthcare #MarketAccess

Nova SBE’s Saúde em Perspetiva podcast asks what Portugal’s National Health Service should want from AI, and where the red lines sit. #SyenzaNews #DigitalHealth #AIinHealthcare

Sandoz has put a date on its golden decade for biosimilars. The Bio100 plan targets more than 100 biosimilars by 2040, about 80% coverage of biosimilar-addressable LoE value from 2035, and a doubling of 2025 net sales. #SyenzaNews #MarketAccess #Biosimilars #ValueCreation

Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory

Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

South Africa has initiated 55,123 people on twice-yearly lenacapavir PrEP in the programme’s first 94 days. Demand is strongest in Gauteng and KwaZulu-Natal; branded supply, second-dose retention and the 2027 generic tender are the real constraints. #SyenzaNews #HIVPrevention #Lenacapavir #MarketAccess

Novartis and The Max Foundation mark 25 years of partnership that has delivered cancer treatment to more than 100,000 patients across 71 LMICs. The next test is whether the model can carry a broader oncology portfolio and transition to country funding.

#SyenzaNews #MarketAccess #GlobalHealth

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA